The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
Subscribe To Our Newsletter & Stay Updated
